Overview

Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully

Status:
RECRUITING

Trial end date:
2028-06-15

Target enrollment:

Participant gender:

Summary

The main objective of the MODULO trial is to compare (non-inferiority) the capacity of DOR/3TC and DTG/3TC two-drug regimens of maintain virological success at W48 in people living with HIV virus ( PLWH) with suppressed HIV plasma viral load (pVL) under three-drug regimen at inclusion. The virological success is defined as no virological failure (2 consecutive pVL 50 copies/mL or one pVL 50 copies/mL followed with discontinuation of treatment or follow-up).

Phase:

PHASE2

Details

Lead Sponsor:

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

Collaborators:

ANRS, Emerging Infectious Diseases
Organization providing support methodology coordination (Institut Pierre Louis d'Epidmiologie et de Sant Publique)

Treatments:

dolutegravir
doravirine
Lamivudine